UK trial assessing AZ’ AZD1775 in head and neck cancer
A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with head and neck cancer has now launched in the UK.
Read More
